FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washir

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

gton, D.C. 20549	OMB APPROVAL

- 1						
	OMB Number:	3235-0287				
ı	Estimated average bu	rden				
	hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					U	JCCII	011 30(11)	or tire	investment C	onipany Act	01 1940						
1. Name and Address of Reporting Person*  CATLIN AVERY W					2. Issuer Name <b>and</b> Ticker or Trading Symbol Celldex Therapeutics, Inc. [ CLDX ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
CALLI	IV AV LIV.	<u> </u>												r (give title	10% Ov Other (s	·	
(Last)		3. Date of Earliest Transaction (Month/Day/Year) 06/10/2015							below)	below) below) Sr. VP & CFO							
C/O CELLDEX THERAPEUTICS, INC.					"	00/10/2013								511 Y 1 CC	J. 0		
53 FRONTAGE ROAD						If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Stroot)					-   4.	it Ame	nament, i	Date (	of Original File	a (Month/Da	y/ Year)	Line		oint/Group Filir	д (Спеск Арр	olicable	
(Street) HAMPT	ON N.	J	08827									2	K Form fi	led by One Re	oorting Persor	n	
					_								Form fi Person	led by More tha	an One Repor	ting	
(City)	(S	tate)	(Zip)														
		Tal	ole I - Non	ı-Deri	vativ	e Se	curitie	s Ac	quired, Di	sposed o	f, or Ber	neficiall	y Owned				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					ear)   i	2A. Deemed Execution Date, if any (Month/Day/Yea		e, Transaction Dispose Code (Instr. 5)		ies Acquire Of (D) (Inst			es Formally (D) (Following (I) (I	n: Direct In or Indirect Enstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)				
									uired, Dis s, options,				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year	ate,	4. Transactior Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Incentive Stock Option	\$25.41	06/10/2015			A		92,000		06/10/2016 <sup>(1)</sup>	06/10/2025	Common Stock	92,000	\$0	92,000	D		

## **Explanation of Responses:**

 $1.\,25\%\ vest\ on\ June\ 10,\,2016\ and\ the\ remainder\ vest\ quarterly\ (in\ equal\ amounts)\ over\ the\ subsequent\ 12\ quarters.$ 

/s/ Anthony S. Marucci,

attorney in fact for Avery W.

Catlin

\*\* Signature of Reporting Person

Date

06/11/2015

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.